Khattab, N. M., M. Abbassi, H. {A Raafat}, and S. Farid, "{A pharmacoeconomic study comparing the use of mycophenolate mofetil or cyclophosphamide as induction therapy in lupus nephritis patients in Egypt}", Lupus: SAGE Publications Sage UK: London, England, pp. 09612033221083270, 2022. Abstract
n/a
Alshabasy, S. A., M. M. Abbassi, M. S. Mohamed, and S. F. Farid, "{A pharmacokinetic study of digoxin holiday dosing practice in Egypt: A prospective-randomized trial}", Bulletin of Faculty of Pharmacy, Cairo University, vol. 54, no. 2: Elsevier, pp. 157–164, 2016. Abstract
n/a
Kamel, A. M., S. F. Farid, A. S. Attia, and M. E. Raziky, "{Association of vitamin D binding protein polymorphisms with response to therapy in Egyptian chronic hepatitis C patients}", The Journal of Infection in Developing Countries, vol. 11, no. 10, pp. 781–790, 2017. Abstract
n/a
Abdelrahman, A. A., A. A. Saad, N. A. Sabry, and S. F. Farid, "{Perceptions of Egyptian physicians about drug shortage during political disturbances: Survey in Greater Cairo}", Bulletin of Faculty of Pharmacy, Cairo University, vol. 54, no. 2: Elsevier, pp. 191–196, 2016. Abstract
n/a
Naguib, S. N., N. A. Sabry, S. F. Farid, and A. M. Alansary, "{Short-term effects of alfacalcidol on hospital length of stay in patients undergoing valve replacement surgery: a randomized clinical trial}", Clinical Therapeutics, vol. 43, no. 1: Elsevier, pp. e1–e18, 2021. Abstract
n/a
Elkassas, N., M. Abbassi, and S. Farid, "{Evaluation of the physician's acceptance to clinical pharmacy interventions after antibiotic stewardship implementation in the ICU in a general hospital in Egypt}", Bulletin of Faculty of Pharmacy, Cairo University, vol. 56, no. 2: Elsevier, pp. 219–223, 2018. Abstract
n/a
Ali, A., S. Farid, M. Amin, M. Kassem, N. Al-Garem, and M. Al-Ghobashy, "{Comparative Clinical Pharmacokinetics of Midodrine and Its Active Metabolite Desglymidodrine in Cirrhotic Patients with Tense Ascites Versus Healthy Volunteers}", Clinical drug investigation, vol. 36, no. 2: Springer, pp. 147–155, 2016. Abstract
n/a
Farid, S., "{The state of pharmacoeconomic research in Egypt}", PharmacoEconomics & Outcomes News, vol. 818, no. 1: Springer, pp. 31–31, dec, 2018. AbstractWebsite
n/a
Naguib, S. N., N. A. Sabry, S. F. Farid, and A. M. Alansary, "Short-term Effects of Alfacalcidol on Hospital Length of Stay in Patients Undergoing Valve Replacement Surgery: A Randomized Clinical Trial.", Clinical therapeutics, vol. 43, issue 1, pp. e1-e18, 2021. Abstract

PURPOSE: Vitamin D deficiency is highly prevalent in critically ill patients, and has been associated with more prolonged length of hospital stay and poor prognosis. Patients undergoing open-heart surgery are at higher risk due to the associated life-threatening postoperative complications. This study investigated the effect of alfacalcidol treatment on the length of hospital stay in patients undergoing valve-replacement surgery.

METHODS: This single-center, randomized, open-label, controlled trial was conducted at El-Demerdash Cardiac Academy Hospital (Cairo, Egypt), from April 2017 to January 2018. This study included adult patients undergoing valve-replacement surgery who were randomized to the intervention group (n = 47; alfacalcidol 2 μg/d started 48 h before surgery and continued throughout the hospital stay) or to the control group (n = 42). The primary end points were lengths of stay (LOS) in the intensive care unit (ICU) and in the hospital. Secondary end points were the prevalence of postoperative hospital-acquired infections, cardiac complications, and in-hospital mortality.

FINDINGS: A total of 86 patients were included in the final analysis, with 51 (59.3%) being vitamin D deficient on hospital admission. Treatment with alfacalcidol was associated with a statistically significant decrease in ICU LOS (hazard ratio = 1.61; 95% CI, 1.77-2.81; P = 0.041) and hospital LOS (hazard ratio = 1.63; 95% CI, 1.04-2.55; P = 0.034). Treated patients had a significantly lower postoperative infection rate than did the control group (35.5% vs 56.1%; P = 0.017). The median epinephrine dose was lower in the intervention group compared to that in the control group (5.9 vs 8.2 mg; P = 0.019). The rate of in-hospital mortality was not significantly different between the 2 groups.

IMPLICATIONS: Early treatment with 2 μg of alfacalcidol in patients undergoing valve-replacement surgery is promising and well tolerated. This effect may be attributed to its immunomodulatory and cardioprotective mechanisms. ClinicalTrials.gov identifier: NCT04085770.

Said, E., S. Mousa, M. Fawzi, N. A. Sabry, and S. Farid, "Combined effect of high-dose vitamin A, vitamin E supplementation, and zinc on adult patients with diabetes: A randomized trial.", Journal of advanced research, vol. 28, pp. 27-33, 2021. Abstract

In type 2 diabetes mellitus (T2DM), hyperglycemia leads to oxidative insult. Vitamins A and E have antioxidant potentials and may help in managing diabetes. The combined effect of high-dose vitamin A plus E supplementation with and without zinc on T2DM, has never been examined. Thus, this study aimed to evaluate and compare the effect of high-dose vitamin A plus E supplementation (AE) versus high-dose vitamin A plus E with zinc (AEZ), on different diabetic parameters. Ninety-eight patients with T2DM were randomized to receive either: 50,000 IU vitamin A and 100 mg vitamin E (AE group, N = 36), an equivalent dose of vitamin A and E combined with 25 mg zinc (AEZ group, N = 35), or no supplements (control group, N = 27) for three months. Compared to control, AEZ group showed significant reductions in fasting blood glucose, 2 h postprandial blood glucose, and glycated hemoglobin (HbA1c) with significant increases in homeostasis model assessment of beta-cell function and difference value of fasting insulin. Two hair loss cases were recorded in both treated groups. Although vitamin A needs dose moderation, these results suggest that, high-dose vitamin A plus E supplementation combined with zinc may improve glycemic control, β-cell function, and insulin secretion in adults with T2DM.